Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.93 |
| ▸ | TSHR | P16473 | 4/20 | 0.93 |
| ▸ | TP53 | P04637 | 2/20 | 0.93 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4598240 | 1.00 | ALDH1A1 (0.93) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL28496175 | 1.00 | ALDH1A1 (0.93) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL472235 | 1.00 | ALDH1A1 (0.93) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL28242907 | 0.97 | ALDH1A1 (0.88) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL28812213 | 0.97 | ALDH1A1 (0.88) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL10577122 | 0.97 | ALDH1A1 (0.88) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL10537879 | 0.97 | ALDH1A1 (0.88) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| Hydrochloric Acid SCHEMBL866231 | 0.97 | ALDH1A1 (0.88) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL1866504 | 0.97 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4TSHRTP53 | |
| SCHEMBL9669 | 0.97 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024061281-A1 | KIT FOR DETECTING PROSTATE CANCER AND USE THEREOF, AND KIT FOR DETECTING BLADDER CANCER AND USE THEREOF | 宁波大学附属第一医院 | 2024-03-28 | — | — | WO | claimed |
| CN-112697720-B | Heparinase detection method based on mercury ion sensitized osmium nanoparticle oxidase activity | 福建医科大学 | 2023-06-06 | — | — | CN | claimed |
| CN-113358592-B | Procyanidine detection method based on sodium alginate-platinum nanoparticle oxidase activity | 福建医科大学 | 2023-06-06 | — | — | CN | claimed |
| CN-112697780-B | Mercury ion colorimetric detection method based on osmium nanoparticle oxidase activity | 福建医科大学 | 2023-06-02 | — | — | CN | claimed |
| CN-114392760-A | Preparation method of iron/nitrogen carbon nanoenzyme with hollow structure | 天津师范大学 | 2022-04-26 | — | — | CN | claimed |
| CN-114100690-A | Bionic catalyst for preparing nuclease by utilizing porous nano material | 南开大学 | 2022-03-01 | — | — | CN | claimed |
| CN-108997139-B | Synthetic method of 3,3',5,5' -tetramethyl benzidine and hydrochloride thereof | 南京艾普特生物医药有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111346676-A | Iron-substituted tungstophosphoric acid polydopamine nano mimic enzyme and preparation method and application thereof | 吉林大学 | 2020-06-30 | — | — | CN | claimed |
| CN-110389125-A | Application of the nano copper selenide as Mimetic Peroxidase detection hydrogen peroxide and L-cysteine | 青岛科技大学 | 2019-10-29 | — | — | CN | claimed |
| CN-107159883-B | Chitosan-nano platinum particle simulates oxidizing ferment | 福建医科大学 | 2019-03-29 | — | — | CN | claimed |
| CN-105628700-B | Hydrogen peroxide detection kit based on bismuth-bovine serum albumin(BSA)-Platinum Nanoparticles | 福建医科大学 | 2018-09-11 | — | — | CN | claimed |
| CN-105548059-B | Folic acid-bovine serum albumin(BSA)-platinum bismuth nanocomposite | 福建医科大学 | 2018-08-24 | — | — | CN | claimed |
| US-20060121451-A1 | Kit and method and device for the preparation of kit for detecting human cytomegalovirus (hCMV) nucleic acid in biological samples | RELIANCE LIFE SCIENCES PRIVATE LIMITED (IN) | 2006-06-08 | — | — | US | claimed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4740016-A1 | BRIGHTFIELD TRIPLEX IMMUNOHISTOCHEMISTRY ASSAY FOR EVALUATING THE COLOCALIZATION OF THE ER, PR, AND KI-67 BIOMARKERS IN CELLS | Ventana Medical Systems, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-0471356-A1 | Antigenic peptide for detecting anti-hepatitis C virus antibodies and use thereof | JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH (JP) | 1992-02-19 | — | — | EP | disclosed |
| EP-0431169-A1 | IMMUNOASSAY METHOD, REAGENT AND KIT | TEIJIN LIMITED (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0410004-A1 | IMMUNOASSAY OF HUMAN OSTEOCALCIN, REAGENT AND KIT THEREFOR | TEIJIN LIMITED (JP) | 1991-01-30 | — | — | EP | disclosed |
| EP-0328939-A2 | Method, reagent, kit and monoclonal antibody for diagnosing cancer in human digestive organs by determining acid glutathione S-transferase | TEIJIN LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | CA2 4654/4885GAA 4275/4885ALDH1A1 2977/4885 |
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | IGLV6-57, GCLC, QPCTL | CA2 4477/4885GAA 3172/4885ALDH1A1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.